Introduction

- Paltusotine is an oral, non-peptide, once daily somatostatin receptor type 2 (SST2) receptor agonist
- Data from healthy volunteers (Phase 1) indicate inhibition of GH-induced GH secretion and lowering of serum IGF-1
- We report the impact on IGF-1 in patients with acromegaly switching from injected SRLs to oral, once daily paltusotine

Study Design

- ACROBAT Edge (NCT03789656) is a single-arm, open-label, dose-blinded study
- Patients switched from injectables SRLs to oral, once daily paltusotine for at least 3 months prior to treatment

Subjects

- 5 groups (Gr) of adult patients (n=47) with acromegaly currently in use
- Analysis performed on Group 1

Group 1 Results

- 25 patients: median age 52 years (31-71); 44% female
- 20 (80%) had prior pituitary surgery
- At baseline 13 (52%) on octreotide; 22% on lanreotide

Conclusions

- Once daily oral paltusotine maintained IGF-1 levels after switching from injected SRL monotherapy
- Both IGF-1 and GH levels promptly rose after withdrawing paltusotine which characterized the magnitude of therapeutic activity of oral paltusotine
- Paltusotine appears to be well tolerated with a safety profile similar to that of SRLs currently in use